Free shipping on all orders over $ 500

BDA-366

Cat. No. M8920
BDA-366 Structure
Size Price Availability
5mg USD 450 4-7 Days
10mg USD 800 4-7 Days
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

BDA-366 is a BCL2 BH4 domain antagonist, that binds BH4 with high affinity and selectivity. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change. Delivery of BDA-366 substantially suppressed the growth of human MM xenografts in NOD-scid/IL2Rγnull mice, without significant cytotoxic effects on normal hematopoietic cells or body weight. Combined BDA-366 and RAD001 treatment exhibits strong synergy against lung cancer in vivo.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 423.51
Formula C24H29N3O4
CAS Number 1821496-27-8
Purity >98%
Solubility DMSO
Storage at -20°C
References

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.
Han B, et al. Cancer Cell. 2015 Jun 8;27(6):852-63. PMID: 26045015.

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Deng J, et al. Oncotarget. 2016 May 10;7(19):27753-63. PMID: 26004684.

Related Bcl-2 Products
A-1331852

A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM.

BTSA1

BTSA1 is a pharmacologically optimized BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. It effectively promotes apoptosis in leukemia cell lines and patient samples while sparing healthy cells.

BH3I-1

BH3I-1 is a Bcl-XL-BH3 domain interaction inhibitor with Ki of 2.4 μM (by fluorescence polarization ).It is a selective inhibitor of Bcl-2 family proteins.

Obatoclax

Obatoclax is an antagonist of Bcl-2 family members containing four Bcl-2 homology domains, including Bcl-2, Bcl-W, Bcl-XL, and Mcl-1 (KD = ~500 nM).

HA14-1

HA14-1 is a Bcl-2 inhibitor that is widely used for studies of apoptosis with IC50 of ~9 μM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: BDA-366 supplier, Bcl-2, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.